ravidasvir
Sign in to saveRavidasvir (PPI-668) is an investigational NS5A inhibitor (by Pharco Pharmaceuticals) in clinical trials for chronic hepatitis C genotype 4.
~3 min read
Encyclopedic overview
1 sectionsContents
- References
{{Drugbox | Verifiedfields = | Watchedfields = | verifiedrevid = | IUPAC_name = (2S)-2-{[Hydroxy(methoxy)methylidene]amino}-1-[(2S)-2-[5-(6-{2-[(2S)-1-[(2S)-2-{[hydroxy(methoxy)methylidene]amino}-3-methylbutanoyl]pyrrolidin-2-yl]-1H-1,3-benzodiazol-6-yl}naphthalen-2-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methylbutan-1-one | image = Ravidasvir.svg | image_class = skin-invert-image | width = 275
| tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration =
Excerpted from Wikipedia’s “ravidasvir” article, available under the CC BY-SA 4.0 licence.